Back to News
Market Impact: 0.25
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Roivant announced topline results from Period 1 of Immunovant's proof-of-concept trial of IMVT-1402 (imeroprubart) for cutaneous lupus erythematosus. The release excerpt provides no efficacy, safety, or statistical outcome data, limiting assessment of the trial's implications for Roivant or Immunovant.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
IMVT0.45
ROIV0.30
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- US aviation sanctions disrupt Iran flights, push travellers overland
- Australia says OpenAI agent hacked Medicare portal
- Meta's standoff with Amazon over Muse could be a sign of things to come
- Mark Zuckerberg debuts $1,299 Meta VR Glasses and Muse Charm pendant amid AI agent push
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund